2 Biotech Stocks to Buy Hand Over Fist in February
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
BioSpace2d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...
Yale Daily News3d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The Motley Fool5d
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
The Washington Post6d
FDA approves new, non-opioid painkiller Journavx
a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex Pharmaceuticals, which makes the drug, has billed it as an effective ...
Axios on MSN6d
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
Yahoo4d
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...
Seeking Alpha6d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential.
Newly approved painkiller Journavx is 'potentially groundbreaking'
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
Yahoo Finance5d
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain. The biotech just won regulatory approval for Journavx ...